We’re facing a bit of an anticlimax this week, now that J.P. Morgan has come and gone. But many happenings await us in the wide world of biopharmaceuticals.
New data on Tourette drug
This week, we’re likely going to see Phase 2 data from Neurocrine Biosciences’ study of Ingrezza, a drug that treats Tourette syndrome. Ingrezza, a dopamine-modulating drug, is also being studied in tardive dyskinesia.
About the Author Reprints
Hello, My friend has an end stage brain cancer, she should to attend in a crispr clinical trial as a last solution, do you have any project about it? If not, please make me aware about other centers, god bless you
New Tourette’s drug; sounds like a head turner.